IMI name change
This article was originally published in The Tan Sheet
Executive Summary
IMI International Medical Innovations will change its name to PreMD Inc. effective in September, the Toronto-based firm announces May 25. The new name "describes the role the company's products fill: predicting disease at an early stage in order to prevent its progression, or from occurring at all." IMI's PREVU-branded skin sterol tests are marketed and distributed by McNeil Consumer Healthcare (1"The Tan Sheet" June 7, 2004, p. 10)...
You may also be interested in...
McNeil Reaches Consumer Cholesterol Testing Licensing Deal With IMI
McNeil Consumer Health is seeking to leverage the potential Rx-to-OTC switch of J&J/Merck's Mevacor (lovastatin) with an agreement to license International Medical Innovations' predictive tests for coronary artery disease (CAD)
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.